Revenues for the quarter amounted to SEK 0.4m (vs. SEK 0.3m in Q1’20/21), relating to customers that use DiviTum for research purposes. Operating expenses increased to SEK 13.6m (10.7m), driven by an increase in FTEs and preparations for the anticipated DiviTum launch, while EBIT was SEK -12.2m (-8.6m). The cash position at the end of the quarter amounted to SEK 130.9m (31.4m) and is expected to suffice for commercialization in the US and Europe and two years of working capital.